Ranganathan, Mohini

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin

Abdallah, C. G., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., Sherif, M., Ahn, K.-H., D’Souza, D. C., Formica, R., et al. (2020) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 184

Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder

D’Souza, D. C., Syed, S. A., Flynn, L. T., Safi-Aghdam, H., Cozzi, N. V., & Ranganathan, M. (2022) · Neuropsychopharmacology

Psychedelics and Drug StudiesTreatment of Major Depression

Cited by 162

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial

Abdallah, C. G., Roache, J. D., Gueorguieva, R., Averill, L. A., Young-McCaughan, S., Shiroma, P. R., Purohit, P., Brundige, A., Murff, W., Ahn, K.-H., et al. (2022) · Neuropsychopharmacology

Posttraumatic Stress Disorder ResearchTreatment of Major Depression

Cited by 111

In vivo evidence of lower synaptic vesicle density in schizophrenia

Radhakrishnan, R., Skosnik, P. D., Ranganathan, M., Naganawa, M., Toyonaga, T., Finnema, S., Hillmer, A. T., Esterlis, I., Huang, Y., Nabulsi, N., et al. (2021) · Molecular Psychiatry

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 100

Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence

D'Souza, D. C., Singh, N., Elander, J., Carbuto, M., Pittman, B., de Haes, J. U., Sjogren, M., Peeters, P., Ranganathan, M., & Schipper, J. (2012) · Neuropsychopharmacology

Schizophrenia research and treatmentTreatment of Major Depression

Cited by 66

Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder

D’Souza, D. C., Radhakrishnan, R., Naganawa, M., Ganesh, S., Nabulsi, N., Najafzadeh, S., Ropchan, J., Ranganathan, M., Cortes-Briones, J., Huang, Y., et al. (2021) · Molecular Psychiatry

Cannabis and Cannabinoid ResearchNeuroscience and Neuropharmacology Research

Cited by 55

mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression

Averill, L. A., Averill, C. L., Gueorguieva, R., Fouda, S., Sherif, M., Ahn, K.-H., Ranganathan, M., D'Souza, D. C., Southwick, S. M., Sanacora, G., et al. (2022) · Journal of Affective Disorders

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 33

Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, Triples the antidepressant Response Rate of Ketamine at 2 Weeks Following Treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial

Abdallah, C., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., D'Souza, D. C., Formica, R., Southwick, S. M., Duman, R. S., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory)

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 30

Acceptability of Mobile Phone-Based Nurse-Delivered Counseling Intervention to Improve HIV Treatment Adherence and Self-Care Behaviors Among HIV-Positive Women in India

Duggal, M., Chakrapani, V., Liberti, L., Satyanarayna, V., Varghese, M., Singh, P., Ranganathan, M., Chandra, P., & Reynolds, N. R. (2018) · AIDS Patient Care and STDs

Mobile Health and mHealth ApplicationsHIV/AIDS Research and Interventions

Cited by 30